Apnimed

Apnimed (Ticker: APMD US) develops oral treatments for obstructive sleep apnea, with its clinical program centered on a single candidate medicine. Its sole clinical drug candidate, AD109, also known as Oxnimbi, combines two medicines and is designed to improve upper-airway muscle activity and prevent airway collapse during sleep. Oxnimbi has been evaluated in approximately 1,300 patients across several Phase 3 trials.

The scheduled listing date on Nasdaq was July 31, 2026. The proposed offering comprises 10,000,000 shares at an indicative price range of $14.00–16.00 per share. At the indicative range midpoint, the base offering would represent $150.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $570.00 million.

BofA Securities, Evercore ISI, Cantor and LifeSci Capital are joint managers.